Long‐COVID symptoms improved after MDMA and psilocybin therapy: A case report
Harman Chopra, Tim Furnish, Monica Verduzco-Gutierrez, David S Jevotovsky, Joel Castellanos
Clinical Case Reports May 28, 2024 DOI: 10.1002/ccr3.8791 via OpenAlex
Summary
AI-generated from the abstractA 41-year-old fully vaccinated woman with Long-COVID syndrome experienced significant symptom relief after self-medicating with psilocybin and MDMA. Long-COVID, a condition persisting after the acute phase of COVID-19, currently lacks effective holistic treatments. This case suggests potential benefit from these substances, but further research is required to evaluate their safety and efficacy.
Study at a glance
| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | 41-year-old fully vaccinated female with Long-COVID syndrome |
| Interventions | Psilocybin MDMA |
| Topics | MDMA Psilocybin Psychedelic-assisted therapy |
| Keywords | Long-covid Covid‐19 Case report Long‐covid |
| Citations | 6 |
| Key finding | A patient with Long-COVID syndrome obtained significant symptomatic relief after self-medicating with psilocybin and MDMA. |
Abstract
Key Clinical Message Long‐COVID syndrome lacks effective holistic treatment options. We present a case of a 41‐year‐old fully vaccinated female with Long‐COVID syndrome who obtained significant symptomatic relief after self‐medicating with psilocybin and MDMA. Abstract Long‐COVID, a syndrome persisting after the acute phase of coronavirus disease 2019 (COVID‐19), lacks effective holistic treatment options. We present a case of a 41‐year‐old fully vaccinated female with Long‐COVID syndrome who obtained significant symptomatic relief by self‐prescribing psilocybin and MDMA. Future research is needed to assess safety and efficacy.